Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

[Hyperemesis gravidarum].

Koot MH, Grooten IJ, Gauw NE, Roseboom TJ, Painter RC.

Ned Tijdschr Geneeskd. 2019 May 3;163. pii: D3591. Dutch.

PMID:
31120218
2.

Variation in hyperemesis gravidarum definition and outcome reporting in randomised clinical trials: a systematic review.

Koot MH, Boelig RC, Van't Hooft J, Limpens J, Roseboom TJ, Painter RC, Grooten IJ.

BJOG. 2018 Nov;125(12):1514-1521. doi: 10.1111/1471-0528.15272. Epub 2018 Jul 2.

PMID:
29727913
3.

Early enteral tube feeding in optimizing treatment of hyperemesis gravidarum: the Maternal and Offspring outcomes after Treatment of HyperEmesis by Refeeding (MOTHER) randomized controlled trial.

Grooten IJ, Koot MH, van der Post JA, Bais JM, Ris-Stalpers C, Naaktgeboren C, Bremer HA, van der Ham DP, Heidema WM, Huisjes A, Kleiverda G, Kuppens S, van Laar JO, Langenveld J, van der Made F, van Pampus MG, Papatsonis D, Pelinck MJ, Pernet PJ, van Rheenen L, Rijnders RJ, Scheepers HC, Vogelvang TE, Mol BW, Roseboom TJ, Painter RC.

Am J Clin Nutr. 2017 Sep;106(3):812-820. doi: 10.3945/ajcn.117.158931. Epub 2017 Aug 9.

PMID:
28793989
4.

Generally Applicable Transformation Protocols for Fluorescent Nanodiamond Internalization into Cells.

Hemelaar SR, van der Laan KJ, Hinterding SR, Koot MV, Ellermann E, Perona-Martinez FP, Roig D, Hommelet S, Novarina D, Takahashi H, Chang M, Schirhagl R.

Sci Rep. 2017 Jul 19;7(1):5862. doi: 10.1038/s41598-017-06180-5.

5.

Peg-interferon plus nucleotide analogue treatment versus no treatment in patients with chronic hepatitis B with a low viral load: a randomised controlled, open-label trial.

de Niet A, Jansen L, Stelma F, Willemse SB, Kuiken SD, Weijer S, van Nieuwkerk CMJ, Zaaijer HL, Molenkamp R, Takkenberg RB, Koot M, Verheij J, Beuers U, Reesink HW.

Lancet Gastroenterol Hepatol. 2017 Aug;2(8):576-584. doi: 10.1016/S2468-1253(17)30083-3. Epub 2017 May 15.

PMID:
28522204
6.

Hyperemesis gravidarum and cardiometabolic risk factors in adolescents: a follow-up of the Northern Finland Birth Cohort 1986.

Koot MH, Grooten IJ, Sebert S, Koiranen M, Järvelin MR, Kajantie E, Painter RC, Roseboom TJ.

BJOG. 2017 Jun;124(7):1107-1114. doi: 10.1111/1471-0528.14534. Epub 2017 Feb 25.

7.

Frequent hepatitis E in the Netherlands without traveling or immunosuppression.

Koot H, Hogema BM, Koot M, Molier M, Zaaijer HL.

J Clin Virol. 2015 Jan;62:38-40. doi: 10.1016/j.jcv.2014.11.020. Epub 2014 Nov 20.

PMID:
25542468
8.

Evaluation of a hepatitis C virus (HCV) antigen assay for routine HCV screening among men who have sex with men infected with HIV.

Vanhommerig JW, van de Laar TJ, Koot M, van Rooijen MS, Schinkel J, Speksnijder AG, Prins M, de Vries HJ, Bruisten SM.

J Virol Methods. 2015 Mar;213:147-50. doi: 10.1016/j.jviromet.2014.11.026. Epub 2014 Dec 18.

PMID:
25528203
9.

Permian-Triassic Osteichthyes (bony fishes): diversity dynamics and body size evolution.

Romano C, Koot MB, Kogan I, Brayard A, Minikh AV, Brinkmann W, Bucher H, Kriwet J.

Biol Rev Camb Philos Soc. 2016 Feb;91(1):106-47. doi: 10.1111/brv.12161. Epub 2014 Nov 27. Review.

PMID:
25431138
10.

Evaluation of a fourth-generation avidity assay for recent HIV infections among men who have sex with men in Amsterdam.

Op de Coul EL, Hogema BM, Sane J, Heijman T, Fennema JS, Murphy G, Koot M.

J Med Microbiol. 2014 Aug;63(Pt 8):1116-7. doi: 10.1099/jmm.0.074518-0. Epub 2014 May 21. No abstract available.

PMID:
24850883
11.

Identifying recently acquired HIV infections among newly diagnosed men who have sex with men attending STI clinics in The Netherlands.

Sane J, Heijman T, Hogema B, Koot M, van Veen M, Götz H, Fennema J, Op de Coul E.

Sex Transm Infect. 2014 Aug;90(5):414-7. doi: 10.1136/sextrans-2013-051420. Epub 2014 Jan 28.

PMID:
24473117
12.

Baseline hepatitis B surface antigen (HBsAg) as predictor of sustained HBsAg loss in chronic hepatitis B patients treated with pegylated interferon-α2a and adefovir.

Takkenberg RB, Jansen L, de Niet A, Zaaijer HL, Weegink CJ, Terpstra V, Dijkgraaf MG, Molenkamp R, Jansen PL, Koot M, Rijckborst V, Janssen HL, Beld MG, Reesink HW.

Antivir Ther. 2013;18(7):895-904.

PMID:
23639931
13.

A self-assembled delivery platform with post-production tunable release rate.

Boekhoven J, Koot M, Wezendonk TA, Eelkema R, van Esch JH.

J Am Chem Soc. 2012 Aug 8;134(31):12908-11. doi: 10.1021/ja3051876. Epub 2012 Jul 26.

PMID:
22823592
14.

Genetic variation in IL28B and treatment outcome in HBeAg-positive and -negative chronic hepatitis B patients treated with Peg interferon alfa-2a and adefovir.

de Niet A, Takkenberg RB, Benayed R, Riley-Gillis B, Weegink CJ, Zaaijer HL, Koot M, Jansen PL, Beld MG, Lopatin U, Reesink HW.

Scand J Gastroenterol. 2012 Apr;47(4):475-81. doi: 10.3109/00365521.2011.648952. Epub 2012 Jan 23.

PMID:
22263608
15.

Use of Immunological and Viral Parameters to Predict Progression of HIV Infection During Natural Course and Antiretroviral Treatment.

Koot M, van 't Wout AB, Miedema F, Schuitemaker H.

BioDrugs. 1997 Oct;8(4):243-9. No abstract available.

PMID:
18020516
16.

Radiographic human identification using bones of the hand: a validation study.

Koot MG, Sauer NJ, Fenton TW.

J Forensic Sci. 2005 Mar;50(2):263-8.

PMID:
15813535
17.
18.

Concurrence of hepatitis B surface antibodies and surface antigen: implications for postvaccination control of health care workers.

Zaaijer HL, Lelie PN, Vandenbroucke-Grauls CM, Koot M.

J Viral Hepat. 2002 Mar;9(2):146-8.

PMID:
11876798
19.

Nonradioactive techniques for measurement of in vitro T-cell proliferation: alternatives to the [(3)H]thymidine incorporation assay.

Messele T, Roos MT, Hamann D, Koot M, Fontanet AL, Miedema F, Schellekens PT, Rinke de Wit TF.

Clin Diagn Lab Immunol. 2000 Jul;7(4):687-92.

20.

Methemoglobinemia as an uncommon cause of cyanosis.

Demirel H, Koster VS, Koot MJ, Ponssen HH, van Vliet AC.

Neth J Med. 1999 Jul;55(1):19-22.

PMID:
10431551
21.

Reduced naive and increased activated CD4 and CD8 cells in healthy adult Ethiopians compared with their Dutch counterparts.

Messele T, Abdulkadir M, Fontanet AL, Petros B, Hamann D, Koot M, Roos MT, Schellekens PT, Miedema F, Rinke de Wit TF.

Clin Exp Immunol. 1999 Mar;115(3):443-50.

22.

Conversion rate towards a syncytium-inducing (SI) phenotype during different stages of human immunodeficiency virus type 1 infection and prognostic value of SI phenotype for survival after AIDS diagnosis.

Koot M, van Leeuwen R, de Goede RE, Keet IP, Danner S, Eeftinck Schattenkerk JK, Reiss P, Tersmette M, Lange JM, Schuitemaker H.

J Infect Dis. 1999 Jan;179(1):254-8.

PMID:
9841850
23.

Low T-cell responses to CD3 plus CD28 monoclonal antibodies are predictive of development of AIDS.

Roos MT, Prins M, Koot M, de Wolf F, Bakker M, Coutinho RA, Miedema F, Schellekens PT.

AIDS. 1998 Oct 1;12(14):1745-51.

PMID:
9792374
24.

Association between CCR5 genotype and the clinical course of HIV-1 infection.

de Roda Husman AM, Koot M, Cornelissen M, Keet IP, Brouwer M, Broersen SM, Bakker M, Roos MT, Prins M, de Wolf F, Coutinho RA, Miedema F, Goudsmit J, Schuitemaker H.

Ann Intern Med. 1997 Nov 15;127(10):882-90.

PMID:
9382366
25.

Identification of Campylobacter jejuni promoter sequences.

Wösten MM, Boeve M, Koot MG, van Nuenen AC, van der Zeijst BA.

J Bacteriol. 1998 Feb;180(3):594-9.

26.

Patterns of T-cell repopulation, virus load reduction, and restoration of T-cell function in HIV-infected persons during therapy with different antiretroviral agents.

Pakker NG, Roos MT, van Leeuwen R, de Jong MD, Koot M, Reiss P, Lange JM, Miedema F, Danner SA, Schellekens PT.

J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Dec 15;16(5):318-26.

PMID:
9420308
27.

Prospective longitudinal analysis of viral load and surrogate markers in relation to clinical progression in HIV type 1-infected persons.

Bruisten SM, Frissen PH, Van Swieten P, Harrigan PR, Kinghorn I, Larder B, Weigel HM, De Vries E, Regez RM, Henrichs JH, Koot M, Huisman JG.

AIDS Res Hum Retroviruses. 1997 Mar 1;13(4):327-35.

PMID:
9071432
28.

Temporal trends of the natural history of HIV-1 infection following seroconversion between 1984 and 1993.

Keet IP, Veugelers PJ, Koot M, de Weerd MH, Roos MT, Miedema F, de Wolf F, Goudsmit J, Coutinho RA.

AIDS. 1996 Nov;10(13):1601-2. No abstract available.

PMID:
8931802
29.
30.

Lower prevalence and incidence of HIV-1 syncytium-inducing phenotype among injecting drug users compared with homosexual men.

Spijkerman IJ, Koot M, Prins M, Keet IP, van den Hoek AJ, Miedema F, Coutinho RA.

AIDS. 1995 Sep;9(9):1085-92.

PMID:
8527083
31.

Envelope V2 configuration and HIV-1 phenotype: clarification.

Schuitemaker H, Fouchier RA, Broersen S, Groenink M, Koot M, van 't Wout AB, Huisman HG, Tersmette M, Miedema F.

Science. 1995 Apr 7;268(5207):115. No abstract available.

PMID:
7755774
32.

Distinct changes in HIV type 1 RNA versus p24 antigen levels in serum during short-term zidovudine therapy in asymptomatic individuals with and without progression to AIDS.

Jurriaans S, Weverling GJ, Goudsmit J, Boogaard J, Brok M, Van Strijp D, Lange J, Koot M, Van Gemen B.

AIDS Res Hum Retroviruses. 1995 Apr;11(4):473-9.

PMID:
7632462
33.

T cell function in vitro is an independent progression marker for AIDS in human immunodeficiency virus-infected asymptomatic subjects.

Roos MT, Miedema F, Koot M, Tersmette M, Schaasberg WP, Coutinho RA, Schellekens PT.

J Infect Dis. 1995 Mar;171(3):531-6.

PMID:
7876598
34.

Immunologic and virologic markers determining progression to AIDS.

Schellekens PT, Koot M, Roos MT, Tersmette M, Miedema F.

J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10 Suppl 2:S62-6. Review.

PMID:
7552515
35.

Immunological and virological markers determining progression to AIDS.

Schellekens PT, Koot M, Roos MT, Tersmette M, Miedema F.

Neth J Med. 1994 Dec;45(6):238-43. Review.

PMID:
7838238
36.

Predictors of disease progression in HIV-infected homosexual men with CD4+ cells < 200 x 10(6)/l but free of AIDS-defining clinical disease.

Keet IP, Krol A, Koot M, Roos MT, de Wolf F, Miedema F, Coutinho RA.

AIDS. 1994 Nov;8(11):1577-83.

PMID:
7848594
37.

The natural history of HIV-1 infection: virus load and virus phenotype independent determinants of clinical course?

Jurriaans S, Van Gemen B, Weverling GJ, Van Strijp D, Nara P, Coutinho R, Koot M, Schuitemaker H, Goudsmit J.

Virology. 1994 Oct;204(1):223-33.

PMID:
7916514
38.

Changing virus-host interactions in the course of HIV-1 infection.

Miedema F, Meyaard L, Koot M, Klein MR, Roos MT, Groenink M, Fouchier RA, Van't Wout AB, Tersmette M, Schellekens PT, et al.

Immunol Rev. 1994 Aug;140:35-72. Review. No abstract available.

PMID:
7821927
39.

Associations between HLA frequencies and pathogenic features of human immunodeficiency virus type 1 infection in seroconverters from the Amsterdam cohort of homosexual men.

Klein MR, Keet IP, D'Amaro J, Bende RJ, Hekman A, Mesman B, Koot M, de Waal LP, Coutinho RA, Miedema F.

J Infect Dis. 1994 Jun;169(6):1244-9.

PMID:
8195600
40.

Characteristics of long-term asymptomatic infection with human immunodeficiency virus type 1 in men with normal and low CD4+ cell counts.

Keet IP, Krol A, Klein MR, Veugelers P, de Wit J, Roos M, Koot M, Goudsmit J, Miedema F, Coutinho RA.

J Infect Dis. 1994 Jun;169(6):1236-43.

PMID:
7910835
41.

Antibody responses to HIV-1 envelope and gag epitopes in HIV-1 seroconverters with rapid versus slow disease progression.

Zwart G, van der Hoek L, Valk M, Cornelissen MT, Baan E, Dekker J, Koot M, Kuiken CL, Goudsmit J.

Virology. 1994 Jun;201(2):285-93.

PMID:
7514319
42.

Production of interleukin-2 by EL4 tumor cells induces natural killer cell- and T-cell-mediated immunity.

Visseren MJ, Koot M, van der Voort EI, Gravestein LA, Schoenmakers HJ, Kast WM, Zijlstra M, Melief CJ.

J Immunother Emphasis Tumor Immunol. 1994 Feb;15(2):119-28.

PMID:
8136944
43.

Recent development on research in AIDS pathogenesis.

Schuitemaker H, Koot M, Miedema F.

Vox Sang. 1994;67 Suppl 3:133-6. Review. No abstract available.

PMID:
7975477
44.

Viral phenotype and T cell reactivity in human immunodeficiency virus type 1-infected asymptomatic men treated with zidovudine.

Koot M, Schellekens PT, Mulder JW, Lange JM, Roos MT, Coutinho RA, Tersmette M, Miedema F.

J Infect Dis. 1993 Sep;168(3):733-6.

PMID:
8102631
45.

Relation of phenotype evolution of HIV-1 to envelope V2 configuration.

Groenink M, Fouchier RA, Broersen S, Baker CH, Koot M, van't Wout AB, Huisman HG, Miedema F, Tersmette M, Schuitemaker H.

Science. 1993 Jun 4;260(5113):1513-6.

PMID:
8502996
46.

Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS.

Koot M, Keet IP, Vos AH, de Goede RE, Roos MT, Coutinho RA, Miedema F, Schellekens PT, Tersmette M.

Ann Intern Med. 1993 May 1;118(9):681-8.

PMID:
8096374
47.

[3 adolescents with hip pain caused by idiopathic chondrolysis].

Koot MF, Berendsen HA, van der Hoeven H, Keessen W, Kuis W.

Ned Tijdschr Geneeskd. 1993 Jan 9;137(2):86-90. Dutch.

PMID:
8421533
48.

Predictors of rapid progression to AIDS in HIV-1 seroconverters.

Keet IP, Krijnen P, Koot M, Lange JM, Miedema F, Goudsmit J, Coutinho RA.

AIDS. 1993 Jan;7(1):51-7.

PMID:
8095146
49.

High pressure liquid chromatographic analysis of the serum concentration of cefuroxime after an intravenous bolus injection of cefuroxime in patients with a coronary artery bypass grafting.

Koot MJ, IJdenberg FN, Stuurman RM, Poell J, Bras LJ, Langemeijer JJ, Lie-A-Huen L.

Pharm Weekbl Sci. 1992 Dec 11;14(6):360-4.

PMID:
1475176
50.

HIV-1 biological phenotype and the development of zidovudine resistance in relation to disease progression in asymptomatic individuals during treatment.

Boucher CA, Lange JM, Miedema FF, Weverling GJ, Koot M, Mulder JW, Goudsmit J, Kellam P, Larder BA, Tersmette M.

AIDS. 1992 Nov;6(11):1259-64.

PMID:
1282015

Supplemental Content

Support Center